FAST Company


Xiretsa is developing innovative therapies for difficult-to-treat bacterial infections. Our proprietary platform technology consists of a novel class of small molecules, known as ACEs, which selectively target bacterial membranes. ACEs are rapidly bactericidal, effective against biofilms and dormant bacteria, and are significantly less prone to acquired resistance relative to traditional antibiotics. Xiretsa is a preclinical company building a portfolio of ACE-based antibiotics for major unmet medical needs including infections caused by multi-drug resistant gram-negative pathogens and chronic lung infections caused by Non-Tuberculous Mycobacteria (NTM).